Additive interaction of levetiracetam with lamotrigine in the mouse 6 Hz psychomotor seizure model – an isobolographic analysis
DOI:
https://doi.org/10.12923/j.2084-980X/26.1/a.18Keywords:
6 Hz psychomotor seizure model, antiepileptic drugs, drug interactions, lamotrigine, levetiracetam, isobolographic analysisAbstract
The aim of this study was to characterize the anticonvulsant effects of levetiracetam (LEV) in combination with lamotrigine (LTG – a second-generation antiepileptic drug), in the mouse 6 Hz psychomotor seizure model. Limbic (psychomotor) seizure activity was evoked in albino Swiss mice by a current (32 mA, 6 Hz, 3 s stimulus duration) delivered via ocular electrodes and isobolographic analysis for parallel dose-response relationship curves (DRRCs) was used to characterize the consequent anticonvulsant interactions between the drug combinations. Results indicated that LEV administered singly was associated with a DRRC that was parallel to that for LTG. With isobolography for parallel DRRCs, the combination of LEV with LTG at three fixed-ratios of 1:3, 1:1 and 3:1 exerted additive interaction. LEV combined with LTG exerted additive interaction in the mouse 6 Hz psychomotor seizure model.
References
1. Barton M.E. et al.: Pharmacological characterization of the 6 Hz psychomotor seizure model of partial epilepsy. Epilepsy Res., 47, 217, 2001.
2. Cheung H., Kamp D., Harris E.: An in vitro investigation of the action of lamotrigine on neuronal voltage-activated sodium channels. Epilepsy Res., 13, 107, 1992.
3. Deckers C.L.P. et al.: Current limitations of antiepileptic drug therapy: a conference review. Epilepsy Res., 53, 1, 2003.
4. Donato Di Paola E. et al.: Influence of levetiracetam on the anticonvulsant efficacy of conventional antiepileptic drugs against audiogenic seizures in DBA/2 mice. Epilepsy Res., 75, 112, 2007.
5. Dudra-Jastrzebska M. et al.: Isobolographic characterization of the anticonvulsant interaction profiles of levetiracetam in combination with clonazepam, ethosuximide, phenobarbital and valproate in the mouse pentylenetetrazole-induced seizure model. Seizure, 18, 607, 2009.
6. Dudra-Jastrzebska M. et al.: Pharmacodynamic and pharmacokinetic interaction profiles of levetiracetam in combination with gabapentin, tiagabine and vigabatrin in the mouse pentylenetetrazole-induced seizure model: An isobolographic analysis. Eur. J. Pharmacol., 605, 87, 2009.
7. EP 2 462 990 A1 (European Patent Application; https://data.epo.org/publication-server/rest/v1.0/publication-dates/20120613/patents/EP2462990NWA1/document.pdf)
8. Gower A.J. et al.: Effects of levetiracetam, a novel antiepileptic drug, on convulsant activity in two genetic rat models of epilepsy. Epilepsy Res., 22, 207, 1995.
9. Gower A.J. et al.: Ucb L059, a novel anti-convulsant drug: pharmacological profile in animals. Eur. J. Pharmacol., 222, 193, 1992. Erratum published in: Eur. J. Pharmacol., 230, 389, 1993.
10. Kaminski R.M. et al.: Benefits of combination therapy in epilepsy: a review of preclinical evidence with levetiracetam. Epilepsia, 50, 387, 2009.
11. Klitgaard H. et al.: Evidence for a unique profile of levetiracetam in rodent models of seizures and epilepsy. Eur. J. Pharmacol., 353, 191, 1998.
12. Leach M.J., Marden C.M., Miller A.A.: Pharmacological studies on lamotrigine, a novel potential antiepileptic drug: II. Neurochemical studies on the mechanism of action. Epilepsia, 27, 490, 1986.
13. Litchfield J.T., Wilcoxon F.: A simplified method of evaluating dose-effect experiments. J. Pharmacol. Exp. Ther., 96, 99, 1949.
14. Loewe S.: The problem of synergism and antagonism of combined drugs. Arzneimittelforschung, 3, 285, 1953.
15. Löscher W., Hönack D.: Profile of ucb L059, a novel anticonvulsant drug, in models of partial and generalized epilepsy in mice and rats. Eur. J. Pharmacol., 232, 147, 1993.
16. Lukyanetz E.A., Shkryl V.M., Kostyuk P.G.: Selective blockade of N-type calcium channels by levetiracetam. Epilepsia, 43, 9, 2002.
17. Lynch B.A. et al.: The synaptic vesicle protein SV2A is the binding site for the antiepileptic drug levetiracetam. Proc. Natl. Acad. Sci. USA, 101, 9861, 2004.
18. Łuszczki J.J. et al.: Pharmacodynamic and pharmacokinetic characterization of interactions between levetiracetam and numerous antiepileptic drugs in the mouse maximal electroshock seizure model: an isobolographic analysis. Epilepsia, 47, 10, 2006.
19. Łuszczki J.J. et al.: Levetiracetam selectively potentiates the acute neurotoxic effects of topiramate and carbamazepine in the rotarod test in mice. Eur. Neuropsychopharmacol., 15, 609, 2005.
20. Łuszczki J.J. et al.: Levetiracetam and felbamate interact both pharmacodynamically and pharmacokinetically: an isobolographic analysis in the mouse maximal electroshock model. Epilepsia, 48, 806, 2007.
21. Łuszczki J.J., Antkiewicz-Michaluk L., Czuczwar S.J.: Isobolographic analysis of interactions between 1-methyl-1,2,3,4-tetrahydroisoquinoline and four conventional antiepileptic drugs in the mouse maximal electroshock-induced seizure model. Eur. J. Pharmacol., 602, 298, 2009.
22. Łuszczki J.J., Czuczwar S.J.: How significant is the difference between drug doses influencing the threshold for electroconvulsions? Pharmacol. Rep., 57, 782, 2005.
23. Łuszczki J.J., Czuczwar S.J.: Isobolographic profile of interactions between tiagabine and gabapentin: a preclinical study. Naunyn-Schmiedebergs Arch. Pharmacol., 369, 434, 2004.
24. Łuszczki J.J., Czuczwar S.J.: Preclinical profile of combinations of some second-generation antiepileptic drugs: an isobolographic analysis. Epilepsia, 45, 895, 2004.
25. Łuszczki J.J. et al.: Isobolographic and behavioral characterizations of interactions between vigabatrin and gabapentin in two experimental models of epilepsy. Eur. J. Pharmacol., 595, 13, 2008.
26. Łuszczki J.J. et al.: Isobolographic analysis of interactions between loreclezole and conventional antiepileptic drugs in the mouse maximal electroshock-induced seizure model. Naunyn-Schmiedebergs Arch. Pharmacol., 373, 169, 2006.
27. Łuszczki J.J. et al.: Isobolographic characterization of interaction of levetiracetam with clobazam in the mouse 6 Hz psychomotor seizure model. J. Pre-Clin. Clin. Res., 6, 25, 2012.
28. Madeja M. et al.: Reduction of voltage-operated potassium currents by levetiracetam: a novel antiepileptic mechanism of action? Neuropharmacology, 45, 661, 2003.
29. Marrosu F. et al.: Levetiracetam attenuates spontaneous spike-and-wave discharges in DBA/2J mice. Epilepsy Res., 75, 224, 2007.
30. Mazarati A.M. et al.: Anticonvulsant effects of levetiracetam and levetiracetam-diazepam combinations in experimental status epilepticus. Epilepsy Res., 58, 167, 2004.
31. Niespodziany I., Klitgaard H., Margineanu D.G.: Levetiracetam inhibits the high-voltage-activated Ca(2+) current in pyramidal neurones of rat hippocampal slices. Neurosci. Lett., 306, 5, 2001.
32. Palma E. et al.: GABA(A)-current rundown of temporal lobe epilepsy is associated with repetitive activation of GABA(A) "phasic" receptors. Proc. Natl. Acad. Sci. USA, 104, 20944, 2007.
33. Patsalos P.N.: Clinical pharmacokinetics of levetiracetam. Clin. Pharmacokinet., 43, 707, 2004.
34. Perucca E.: Pharmacological principles as a basis for polytherapy. Acta Neurol. Scand. Suppl., 162, 31, 1995.
35. Rigo J.M. et al.: The anti-epileptic drug levetiracetam reverses the inhibition by negative allosteric modulators of neuronal GABA- and glycine-gated currents. Br. J. Pharmacol., 136, 659, 2002.
36. Sills G.J. et al.: Pharmacodynamic interaction studies with topiramate in the pentylenetetrazol and maximal electroshock seizure models. Seizure, 13, 287, 2004.
37. Stefani A., Spadoni F., Bernardi G.: Voltage-activated calcium channels: targets of antiepileptic drug therapy? Epilepsia, 38, 959, 1997.
38. Tallarida R.J. (2000). Drug synergism and dose-effect data analysis. Chapman & Hall/CRC, Boca Raton, USA.
39. Vinogradova L.V., van Rijn C.M.: Anticonvulsive and antiepileptogenic effects of levetiracetam in the audiogenic kindling model. Epilepsia, 49, 1160, 2008.
40. Wojda E. et al.: Isobolographic characterization of interactions of levetiracetam with the various antiepileptic drugs in the mouse 6 Hz psychomotor seizure model. Epilepsy Res., 86, 163, 2009.
41. Zona C. et al.: Levetiracetam does not modulate neuronal voltage-gated Na+ and T-type Ca2+ currents. Seizure, 10, 279, 2001.
Downloads
Published
Issue
Section
License
Copyright (c) 2013 Authors
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 Unported License.
